Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Akebia Therapeutics Inc. shares valued at $15,140 were sold by Hadas Nicole R. on May 13 ’24. At $1.26 per share, Hadas Nicole R. sold 12,016 shares. The insider’s holdings dropped to 651,243 shares worth approximately $0.94 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Dahan Michel sold 34,840 shares, netting a total of over 43,898 in proceeds. Following the sale of shares at $1.26 each, the insider now holds 672,092 shares.
Before that, Dahan Michel had sold 8,661 shares from its account. In a trade valued at $13,684, the SVP, Chief Operating Officer traded Akebia Therapeutics Inc. shares for $1.58 each. Upon closing the transaction, the insider’s holdings decreased to 8,661 shares, worth approximately $1.02 million.
Analysts at H.C. Wainwright upgraded the stock from ‘”a Neutral”‘ to ‘”a Buy”‘ outlook in a report released in late August. As of May 31, 2023, Piper Sandler has increased its “Neutral” rating to a “an Overweight” for AKBA. Earlier on March 31, 2022, Piper Sandler downgraded its rating. Their new recommendation was “a Neutral” for AKBA stock which previously was a “an Overweight”.
Analyzing AKBA Stock Performance
During the last five days, there has been a surge of approximately 3.23%. Over the course of the year, Akebia Therapeutics Inc. shares have jumped approximately 16.13%. Shares of the company reached a 52-week high of $2.4800 on 03/28/24 and a 52-week low of $0.8000 on 06/26/24. A 50-day SMA is recorded $1.3347, while a 200-day SMA reached $1.3566. Nevertheless, trading volume fell to 1.14 million shares from 1.24 million shares the previous day.
Support And Resistance Levels for Akebia Therapeutics Inc. (AKBA)
According to the 24-hour chart, there is a support level at 1.4167, which, if violated, would cause prices to drop to 1.3933. In the upper region, resistance lies at 1.4667. The next price resistance is at 1.4933. RSI (Relative Strength Index) is 52.75 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.0208, which suggests the price will decrease in the coming days. Percent R is at 45.16%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
